All News

2020

January

Media Release / Jan 20, 2020

Novartis announces EU approval of Mayzent® (siponimod) for adult patients with secondary progressive multiple sclerosis (SPMS) with active disease

Read More
San Francisco bridge by Joseph Barrientos @jbcreate_/Unsplash
Featured News / Jan 13, 2020

Novartis @ J.P Morgan 2020

From January 13th to 16th 2020, Novartis is attending the J.P Morgan Healthcare Conference in San Francisco.

Read More
Story / Jan 09, 2020

Sourcing innovation, strategically

Phil Gotwals talks about his vision for the future of business development for research.

Read More
Media Release / Jan 09, 2020

Novartis ligelizumab (QGE031) more effective than Xolair® at inhibiting immunoglobulin E pathway responsible for chronic spontaneous urticaria

Read More
Media Release / Jan 06, 2020

Novartis successfully completes acquisition of The Medicines Company, adding a potentially first-in-class, investigational cholesterol-lowering therapy inclisiran

Read More
Media Release / Jan 06, 2020

Novartis completes tender offer for all outstanding shares of The Medicines Company

Read More

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society report.

Learn More